1379
ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 5
THE IMPORTANCE AND BENEFITS OF IVABRADINE IN CHRONIC HEART
FAILURE
Odilov Azim Jamil o’g’li
Student at Asian International University.
Bukhara, Uzbekistan.
https://doi.org/10.5281/zenodo.15515427
Abstract. Chronic heart failure (CHF) is a condition characterized by the heart’s
inability to pump blood effectively, leading to insufficient blood flow to meet the div’s needs.
This results in symptoms such as fatigue, breathlessness, and fluid retention. Heart failure is
often associated with a variety of comorbidities and requires a comprehensive treatment
approach. Among the medications used to manage CHF, Ivabradine has gained attention for its
specific benefits in controlling heart rate and improving patient outcomes.
Keywords: Chronic heart failure, Ivabradine, long-term risk of cardiac remodeling, beta-
blockers.
1.
What is Ivabradine?
Ivabradine is a medication that specifically reduces the heart rate by inhibiting the If
(funny) channels in the sinoatrial (SA) node, which is responsible for regulating heart rate.
Unlike beta-blockers, which also lower heart rate but affect other aspects of the sympathetic
nervous system, Ivabradine works exclusively on the heart's pacemaker cells without affecting
blood pressure or causing other systemic side effects typically associated with beta-blockers.
2.
Role of Ivabradine in Chronic Heart Failure
In chronic heart failure, elevated heart rate is a common finding and often contributes to
worsening symptoms. The heart tries to compensate for its decreased pumping efficiency by
increasing its rate of contraction. However, an abnormally high heart rate can be detrimental,
causing increased myocardial oxygen demand, decreased diastolic filling time, and worsened
cardiac function over time. Ivabradine helps reduce heart rate without compromising cardiac
output, making it particularly beneficial in managing symptoms and improving the prognosis for
patients with heart failure.
3.
Benefits of Ivabradine in Heart Failure
a.
Improved Symptom Control
One of the key benefits of Ivabradine in chronic heart failure is its ability to reduce
symptoms such as fatigue, shortness of breath, and exercise intolerance. By lowering the heart
rate, Ivabradine allows more time for the heart to fill with blood between beats, improving
overall cardiac efficiency. This can directly alleviate symptoms, making it easier for patients to
engage in daily activities.
b.
Reduced Hospitalization Rates
Studies have shown that Ivabradine can help reduce the number of hospitalizations in
heart failure patients. By controlling heart rate and improving cardiac efficiency, Ivabradine
helps prevent exacerbations of heart failure that often lead to hospitalization. This is particularly
important as repeated hospitalizations for heart failure are associated with a worse prognosis and
a higher risk of mortality.
c.
Cardioprotective Effects
In addition to its effects on heart rate, Ivabradine has demonstrated potential
cardioprotective benefits. By reducing the workload on the heart, Ivabradine may help preserve
1380
ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 5
myocardial function over time, reducing the long-term risk of cardiac remodeling (the process by
which the heart's structure and function become progressively impaired in heart failure).
d.
Improved Prognosis and Survival
Ivabradine has been shown to improve survival rates in patients with chronic heart
failure. In clinical trials, patients treated with Ivabradine, particularly those with heart failure and
a resting heart rate above 70 beats per minute, experienced improved outcomes, including
reduced mortality and a lower incidence of cardiovascular events.
4.
Ivabradine in Combination with Other Medications
Ivabradine is often used in combination with other heart failure treatments, such as
ACE
inhibitors
,
beta-blockers
,
diuretics
, and
aldosterone antagonists
. While beta-blockers are
commonly used to control heart rate in heart failure, Ivabradine is a valuable alternative for
patients who cannot tolerate beta-blockers due to side effects, such as fatigue or hypotension.
Ivabradine works synergistically with these medications, enhancing the overall therapeutic effect
and improving patient outcomes.
5.
Indications and Usage
Ivabradine is particularly recommended for patients with stable chronic heart failure who
meet the following criteria:
•
They have a
resting heart rate
of 70 beats per minute or more.
•
They are already on standard heart failure therapy, including
beta-blockers
(if
tolerated),
ACE inhibitors
, or
ARBs
.
•
They are in
New York Heart Association (NYHA) class II-III
heart failure.
It is important to note that Ivabradine should not be used in patients with
sick sinus
syndrome
,
severe hepatic impairment
, or
acute decompensated heart failure
, and caution is
advised when using it in patients with other heart rhythm abnormalities.
6.
Side Effects and Considerations
While Ivabradine is generally well-tolerated, it is not without potential side effects. The
most common adverse effects include:
•
Bradycardia
(slow heart rate), which can be dangerous if it becomes too
pronounced.
•
Visual disturbances
: Some patients may experience transient visual symptoms,
such as brightness or phosphenes (visual halos), due to the drug’s effect on the retina.
•
Headache
: This is a common side effect, particularly during the initiation of
treatment.
These side effects are generally mild and reversible, but careful monitoring of the
patient’s heart rate and visual symptoms is required during treatment.
7.
Conclusion
Ivabradine has emerged as an important addition to the treatment arsenal for chronic heart
failure. By specifically targeting the heart rate and improving myocardial efficiency, Ivabradine
helps alleviate symptoms, reduce hospitalizations, and improve long-term outcomes. Its unique
mechanism of action, which focuses on the sinoatrial node without affecting other aspects of
cardiovascular function, makes it a valuable tool for patients who are unable to tolerate beta-
blockers or need additional heart rate control. When used appropriately and in combination with
other therapies, Ivabradine can significantly enhance the quality of life and survival for patients
with chronic heart failure.
1381
ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 5
REFERENCES
1.
Saodat, A., Vohid, A., Ravshan, N., & Shamshod, A. (2020). MRI study in patients with
idiopathic cokearthrosis of the hip joint.
International Journal of Psychosocial
Rehabilitation
,
24
(2), 410-415.
2.
Axmedov, S. J. (2023). EFFECTS OF THE DRUG MILDRONATE.
Innovative
Development in Educational Activities
,
2
(20), 40-59.
3.
Jamshidovich, A. S. (2023). ASCORBIC ACID: ITS ROLE IN IMMUNE SYSTEM,
CHRONIC INFLAMMATION DISEASES AND ON THE ANTIOXIDANT
EFFECTS.
EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE
,
3
(11),
57-60.
4.
Jamshidovich, A. S. (2023). THE ROLE OF THIOTRIAZOLINE IN THE
ORGANISM.
Ta'lim innovatsiyasi va integratsiyasi
,
9
(5), 152-155.
5.
Jamshidovich,
A.
S.
(2023).
HEPTRAL
IS
USED
IN
LIVER
DISEASES.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
35
(3),
76-78.
6.
Jamshidovich, A. S. (2023). EFFECT OF TIVORTIN ON CARDIOMYOCYTE CELLS
AND ITS ROLE IN MYOCARDIAL INFARCTION.
Gospodarka i Innowacje.
,
42
, 255-
257.
7.
Jamshidovich,
A.
S.
(2024).
NEUROPROTECTIVE
EFFECT
OF
CITICOLINE.
EUROPEAN
JOURNAL
OF
MODERN
MEDICINE
AND
PRACTICE
,
4
(1), 1-4.
8.
Jamshidovich, A. S. (2024). THE ROLE OF TRIMETAZIDINE IN ISCHEMIC
CARDIOMYOPATHY.
Journal of new century innovations
,
44
(2), 3-8.
9.
Jamshidovich,
A.
S.
(2024).
ВСЕ
ЭФФЕКТЫ
ПРЕПАРАТА
ИМУДОН.
TADQIQOTLAR
,
31
(2), 39-43.
10.
Jamshidovich, A. S. (2024). SPECIFIC FEATURES OF THE EFFECT OF THE
HEPARIN DRUG.
TADQIQOTLAR
,
31
(2), 34-38.
11.
Jamshidovich, A. S. (2024). USE OF GLUCOCORTICOSTEROIDS IN PEDIATRIC
PRACTICE.
TADQIQOTLAR
,
31
(2), 29-33.
12.
Jamshidovich,
A.
S.
(2024). РОЛЬ ИНТЕЛЛАНОВОГО СИРОПА И
ЦИАНОКОБАЛАМИНА В УЛУЧШЕНИИ ПАМЯТИ.
TADQIQOTLAR
,
31
(2), 44-48.
13.
Jamshidovich, A. S. (2024). TREATMENT OF POLYNEUROPATHY WITH
BERLITHION.
Ta'limning zamonaviy transformatsiyasi
,
4
(1), 201-209.
14.
Jamshidovich,
A.
S.
(2024).
USE
OF
ASCORIL
IN
BRONCHIAL
ASTHMA.
Ta'limning zamonaviy transformatsiyasi
,
4
(1), 191-200.
15.
Jamshidovich,
A.
S.
(2024).
THE
IMPORTANCE
OF
THE
DRUG
ARTOXAN.
Ta'limning zamonaviy transformatsiyasi
,
4
(1), 182-190.
16.
Jamshidovich, A. S. (2024). THE ROLE OF RENGALIN IN CHRONIC
BRONCHITIS.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В
МИРЕ
,
38
(4), 116-123.
17.
Jamshidovich, A. S. (2024). THE ROLE OF ALMAGEL DRUG IN GASTRIC AND
DUODENAL WOUND DISEASE.
Ta'limning zamonaviy transformatsiyasi
,
4
(1), 173-
181.
1382
ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 5
18.
Jamshidovich, A. S. (2024). THE ROLE OF CODELAK BRONCHO SYRUP IN
CHILDREN'S PRACTICE.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ
В МИРЕ
,
38
(4), 109-115.
19.
Jamshidovich, A. S. (2024). THE AEVIT DRUG EFFECT.
ОБРАЗОВАНИЕ НАУКА
И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
38
(4), 124-132.
20.
Jamshidovich, A. S. (2024). THE IMPORTANCE OF ALCHEBA DRUG IN POST-
STROKE APHASIA.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В
МИРЕ
,
38
(4), 132-138.
21.
Jamshidovich, A. S. (2024). THE ROLE OF HYALURON CHONDRO DRUG IN
OSTEOARTHROSIS.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В
МИРЕ
,
38
(4), 139-145.
22.
Jamshidovich,
A.
S.
(2024).
EFFECT
OF
SIMETHICONE
DROP
IN
FLATULENCE.
Лучшие интеллектуальные исследования
,
14
(1), 95-101.
23.
Jamshidovich, A. S. (2024). BENEFITS OF BETADINE SOLUTION.
Лучшие
интеллектуальные исследования
,
14
(1), 116-122.
24.
Jamshidovich, A. S. (2024). EFFECT INHALED GLUCOCORTICOIDS IN
CHRONIC
OBSTRUCTIVE
PULMONARY
DISEASE
AND
BRONCHIAL
ASTHMA.
TADQIQOTLAR
,
31
(1), 171-180.
25.
Jamshidovich, A. S. (2024). USE OF VIGANTOL IN RICKETS.
Лучшие
интеллектуальные исследования
,
14
(1), 102-108.
26.
Jamshidovich, A. S. (2024). THE VITAPROST DRUG RESULTS.
Лучшие
интеллектуальные исследования
,
14
(1), 109-115.
27.
Jamshidovich, A. S. (2024). THE ROLE OF BISEPTOL DRUG IN URINARY
TRACT DISEASE.
Лучшие интеллектуальные исследования
,
14
(1), 89-94.
28.
Jamshidovich,
A.
S.
(2024).
PROPERTIES
OF
THE
DRUG
DORMIKIND.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В
МИРЕ
,
38
(5), 88-92.
29.
Jamshidovich, A. S., & Komilovich, E. B. (2024). IMMUNOMODULATORY
FUNCTION OF DIBAZOL DRUG.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ
ИДЕИ В МИРЕ
,
38
(5), 83-87.
30.
Jamshidovich, A. S., & Komilovich, E. B. (2024). ADVANTAGES OF THE DRUG
HEPTRAL.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
38
(5),
98-101.
31.
Эргашов, Б. К., & Ахмедов, Ш. Ж. (2024). ГИПЕРТОНИЧЕСКАЯ БОЛЕЗНЬ
ЭТИОЛОГИЯ.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В
МИРЕ
,
38
(6), 59-69.
32.
Komilovich,
E.
B.,
&
Jamshidovich,
A.
S.
(2024).
HYPERTENSION,
CLASSIFICATION
AND
PATHOGENESIS.
ОБРАЗОВАНИЕ
НАУКА
И
ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
38
(6), 50-58.
33.
Komilovich, E. B., & Jamshidovich, A. S. (2024). YURAK ISHEMIYASI.
STENOKARDIYADA SHOSHILINCH TIBBIY YORDAM.
ОБРАЗОВАНИЕ НАУКА
И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
38
(6), 12-20.
34.
Komilovich,
E.
B.,
&
Jamshidovich,
A.
S.
(2024).
HYPERTENSION
ETIOLOGY.
ОБРАЗОВАНИЕ
НАУКА
И
ИННОВАЦИОННЫЕ
ИДЕИ
В
МИРЕ
,
38
(6), 32-41.
1383
ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 5
35.
Komilovich, E. B., & Jamshidovich, A. S. (2024). CARDIAC ISCHEMIA. ANGINA
NURSING DIAGNOSIS AND CARE.
Journal of new century innovations
,
46
(1), 44-52.
36.
Jamshidovich, A. S. (2024). IMPORTANT INDICATIONS OF THE DRUG
WOBENZYM.
Journal of new century innovations
,
46
(1), 29-32.
37.
Jamshidovich, A. S. (2024). THE RESULTS OF THE EFFECT OF THE DRUG
VALIDOL.
Journal of new century innovations
,
46
(1), 19-23.
38.
Jamshidovich, A. S. (2024). VIFERON USE IN CHILDREN.
Journal of new century
innovations
,
46
(1), 24-28.
39.
Jamshidovich,
A.
S.
(2024).
USE
OF
DUSPATALIN
(MEBEVERINE
HYDROCHLORIDE)
IN
GASTROINTESTINAL
DISEASES.
ОБРАЗОВАНИЕ
НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
38
(5), 93-97.
40.
Jamshidovich, A. S. (2024). ЭФФЕКТЫ СИРОПА ДЕПАКИНА (ВАЛЬПРОЕВАЯ
КИСЛОТА).
Ta'lim innovatsiyasi va integratsiyasi
,
14
(2), 148-152.
41.
Jamshidovich, A. S., & Komilovich, E. B. (2024). THE IMPORTANCE OF THE
DRUG ALLOCHOL FOR CHRONIC CHOLECYSTITIS.
Ta'lim innovatsiyasi va
integratsiyasi
,
14
(2), 133-137.
42.
Jamshidovich, A. S., & Komilovich, E. B. (2024). ВАЖНЫЕ СВОЙСТВА
ПРЕПАРАТА
ДЕ-НОЛ
(субцитрат
висмута).
Ta'lim
innovatsiyasi
va
integratsiyasi
,
14
(2), 143-147.
43.
Jamshidovich, A. S., & Komilovich, E. B. (2024). SPECIAL FEATURES OF
BUDECTON DRUG.
Ta'lim innovatsiyasi va integratsiyasi
,
14
(2), 138-142.
44.
Jamshidovich, A. S. (2024). ЭФФЕКТИВНОЕ ВОЗДЕЙСТВИЕ ПРЕПАРАТА
КЕЙВЕР.
Ta'lim innovatsiyasi va integratsiyasi
,
15
(3), 137-143.
45.
Jamshidovich,
A.
S.
(2024).
USEFUL
PROPERTIES
OF
THE
DRUG
YODOFOL.
Ta'lim innovatsiyasi va integratsiyasi
,
15
(3), 144-149.
46.
Jamshidovich, A. S. (2024). FITOTERAPIYANING AKUSHER-GINEKOLOGIYADA
AHAMIYATI.
Лучшие интеллектуальные исследования
,
15
(2), 121-125.
47.
Jamshidovich,
A.
S.
(2024).
THE
IMPORTANCE
OF
THE
DRUG
DOPROKIN.
Лучшие интеллектуальные исследования
,
15
(2), 109-114.
48.
Jamshidovich, A. S. (2024). THE EFFECT OF DOSTINEX ON THE BODY.
Лучшие
интеллектуальные исследования
,
15
(2), 115-120.
49.
Jamshidovich, A. S. (2024). РЕЗУЛЬТАТЫ ЭФФЕКТИВНОГО ДЕЙСТВИЯ
ПРЕПАРАТА КАНЕФРОН.
Лучшие интеллектуальные исследования
,
15
(2), 138-
143.
50.
Jamshidovich, A. S. (2024). СОВРЕМЕННЫЕ ЭФФЕКТЫ ПРЕПАРАТА
ИНДОЛ.
Лучшие интеллектуальные исследования
,
15
(2), 126-131.
51.
Jamshidovich, A. S. (2024). EFFECT OF ISMIZHEN DRUG ON BODY
IMMUNITY.
Лучшие интеллектуальные исследования
,
15
(2), 132-137.
52.
Jamshidovich, A. S. (2024). POSITIVE EFFECTS OF THE DRUG CARCIL.
Ta'lim
innovatsiyasi va integratsiyasi
,
15
(3), 127-131.
53.
Jamshidovich, A. S. (2024). PЕЗУЛЬТАТЫ ЭФФЕКТИВНОГО ДЕЙСТВИЯ
KАВИНТОНА.
Ta'lim innovatsiyasi va integratsiyasi
,
15
(3), 132-136.
54.
Jamshidovich, A. S. (2024). Современный Эффект Спрея Мометазон.
Research
Journal of Trauma and Disability Studies
,
3
(3), 62-65.
1384
ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 5
55.
Jamshidovich, A. S. (2024). THE ROLE OF" SIMONTE PLUS" DRUG IN THE
MODERN TREATMENT OF BRONCHIAL ASTHMA.
EUROPEAN JOURNAL OF
MODERN MEDICINE AND PRACTICE
,
4
(5), 66-70.
56.
Jamshidovich, A. S. (2024). FEATURES OF THE BIOMECHANISM OF THE DRUG
LEVOMYCETIN (CHLORAMPHENICOL).
EUROPEAN JOURNAL OF MODERN
MEDICINE AND PRACTICE
,
4
(9), 298-301.
57.
Jamshidovich, A. S. (2024). THE MOST IMPORTANT INDICATORS OF OMEGA 3
SUBSTANCE IN THE METABOLISM OF THE HUMAN BODY.
EUROPEAN
JOURNAL OF MODERN MEDICINE AND PRACTICE
,
4
(10), 113-117.
58.
Komilovich, E. B., & Khalimovich, M. N. (2024). CARDIAC ISCHEMIA. ANGINA
CLINICAL FORMS AND DIAGNOSIS.
Journal of new century innovations
,
46
(1), 70-
78.
59.
Komilovich, E. B. (2024). CORONARY HEART DISEASE. ANGINA EMERGENCY
CARE.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
38
(7), 235-
242.
60.
Komilovich, E. B. (2024). YURAK ISHEMIK KASALLIGI. STENOKARDIYANI
DAVOLASHNING ZAMONAVIY TAMOYILLARI.
ОБРАЗОВАНИЕ НАУКА И
ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
38
(6), 3-11.
61.
Jamshidovich, A. S. (2024). THE MOST IMPORTANT BENEFITS OF GINGER FOR
THE HUMAN BODY'S IMMUNITY.
EUROPEAN JOURNAL OF MODERN
MEDICINE AND PRACTICE
,
4
(11), 269-273.
62.
Axmedov, S. (2024). THE SPECIFIC EFFECT OF THE DRUG" BAKLASAN" IN
CEREBROVASCULAR DISEASES AND ITS PRACTICAL SIGNIFICANCE
TODAY.
Modern Science and Research
,
3
(12), 485-492.
63.
Komilovich, E. B. Z. (2023). Coronary Artery Disease.
EUROPEAN JOURNAL OF
MODERN MEDICINE AND PRACTICE
,
3
(12), 81-87.
64.
Komilovich,
E.
B.
(2024).
CORONARY
HEART
DISEASE.
ANGINA
TREATMENT.
Journal of new century innovations
,
46
(1), 95-104.
65.
Komilovich, E. B. (2024). HYPERTENSION TREATMENT.
ОБРАЗОВАНИЕ НАУКА
И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
38
(7), 227-234.
66.
Эргашов, Б. К. (2024). ИШЕМИЧЕСКАЯ БОЛЕЗНЬ СЕРДЦА. СТЕНОКАРДИЯ
ПРОФИЛАКТИКА.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В
МИРЕ
,
38
(6), 21-31.
67.
Axmedov, S. (2025). ВАЖНЫЕ СВОЙСТВА ПРЕПАРАТА ЭСКУЗАН ПРИ
СОСУДИСТЫХ ЗАБОЛЕВАНИЯХ.
Modern Science and Research
,
4
(1), 380-387.
68.
Эргашов,
Б.
К.
(2024).
ГИПЕРТОНИЧЕСКАЯ
БОЛЕЗНЬ
ДИАГНОСТИКА.
ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В
МИРЕ
,
38
(6), 70-78.
69.
Komilovich, E. B. (2024). HYPERTENSION DIAGNOSTICS.
ОБРАЗОВАНИЕ
НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ
,
38
(6), 42-49.
70.
Xusenovich, M. S., & Turаpjаnovnа, Z. M. (2024). SEMIZLIKNING TURLI
FENOTIPLARDA KARDIOMETABOLIK XAVF OMILLARINI TAQQOSLASH.
SO
‘NGI ILMIY TADQIQOTLAR NAZARIYASI
,
7
(4), 112-116.
1385
ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 5
71.
Husenovich, M. S., & Turabdjanovna, Z. M. (2024). STUDY OF DIURNAL PROFILE
OF
ARTERIAL
HYPERTENSION
IN
DIFFERENT
PHENOTYPE
OBESITY.
образование наука и инновационные идеи в мире
,
43
(1), 129-131.
72.
Xusenovich, M. S. (2024, September). SEMIZLIKNI TURLI FENOTIPLARIDA
YURAK QON-TOMIR KASALLIKLARINI KELIB CHIQISH XAVFI PROGNOZI.
In
INTERNATIONAL SCIENTIFIC RESEARCH CONFERENCE
(Vol. 3, No. 26, pp. 15-
18).
73.
Xusenovich, M. S. (2024). O ‘ZBEKISTONDA RESPUBLIKASIDA YURAK-QON
TOMIR
KASALLIKLARI
TARQALISHI
VA
HOZIRGI
KUNDAGI
KO’RILAYOTGAN CHORA TADBIRLAR.
AMERICAN JOURNAL OF SOCIAL
SCIENCE
,
2
(3), 79-82.
74.
Xusenovich, M. S., & Allayarovich, A. A. (2024). O ‘ZBEKISTONDA YURAK-QON
TOMIR
KASALLIKLARI
TARQALISHI
VA
HOZIRGI
KUNDAGI
TENDENSIYASI.
MODELS AND METHODS FOR INCREASING THE EFFICIENCY
OF INNOVATIVE RESEARCH
,
4
(38), 54-57.
75.
Ravshanovna, X. L. (2021, June). MINIMALLY INVASIVE METHODS OF
TREATMENT OF DENTAL CARIES IN ADULTS. In
" ONLINE-CONFERENCES"
PLATFORM
(pp. 118-119).
76.
Axmedov, S. (2025). SPECIFIC PROPERTIES OF ROXERA DRUG IN
CARDIOVASCULAR DISEASES.
Modern Science and Research
,
4
(2), 472-479.
77.
Axmedov, S. (2025). THE DRUG PHYSIOTENS, THE FEATURES OF THE DRUG
AND ITS USE IN THE FIELD OF CARDIOLOGY, IN PATIENTS WITH HEAVY
BODY WEIGHT.
Modern Science and Research
,
4
(3), 350-358.
78.
Axmedov, S. (2025). THE USE OF MIRENA IN GYNECOLOGIC DISEASES AND
ITS SIGNIFICANCE.
Modern Science and Research
,
4
(4), 304-312.
79.
Axmedov, S. (2025). THE ROLE, FUNCTIONS AND IMPORTANCE OF
GLUTAMIC ACID IN THE HUMAN BODY.
Modern Science and Research
,
4
(5).
